Actinium Pharmaceuticals faces a precarious financial outlook as it attempts to transition its Iomab-B and ARC platforms toward commercialization while managing a rapidly eroding equity base. The company's reliance on sporadic milestone payments and significan...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 7, 2026 | $0.89+545.0% vs -$0.20 | $35M+0.0% vs $35M |
Q2 2026 May 8, 2026 | -$0.18+18.2% vs -$0.22 | — vs $3M |
Q2 2026 Mar 30, 2026 | -$0.19-1.8% vs -$0.19 | — vs $600,000 |
Q4 2025 Nov 14, 2025 | -$0.16+36.0% vs -$0.25 | $90,000+33.3% vs $67,500 |
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sandesh Seth, Chairman and Chief Executive Officer, will present at the H.C.
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Actinium Pharmaceuticals and
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Palatin Technologies (OTCMKTS:PTNT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Valuation and Earnings This table compares Actinium
Benchmark ATNM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Actinium Pharmaceuticals, Inc. (ATNM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.18 | $37.02M | -1.08 | — | -37652.22% | -166.96% | — | |
| $7.87 | $231.23M | -1.57 | -92.81% | -10422.48% | — | — | |
| $1.01 | $10.08M | -0.84 | — | -112028.8% | — | — | |
| $6.99 | $557.09M | -2.31 | 216.93% | -34% | — | — | |
| $2.80 | $58.88M | -0.54 | -3.98% | -1875.52% | -111.53% | — | |
| $6.84 | $2.49B | 22.02 | 43.31% | 8.11% | 7.77% | — |
Actinium Pharmaceuticals, Inc. (ATNM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Actinium Pharmaceuticals, Inc. (ATNM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Jun 18, 2026·SEC
May 29, 2026·SEC
Get notified when ATNM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Actinium Pharmaceuticals, Inc. (ATNM) stock FAQ — growth, dividends, profitability & financials explained
Actinium Pharmaceuticals, Inc. (ATNM) reported $35.1M in revenue for fiscal year 2025.
Yes, Actinium Pharmaceuticals, Inc. (ATNM) is profitable, generating $11.3M in net income for fiscal year 2025 (-37652.2% net margin).
Actinium Pharmaceuticals, Inc. (ATNM) has a return on equity (ROE) of -167.0%. Negative ROE indicates the company is unprofitable.
Actinium Pharmaceuticals, Inc. (ATNM) had negative free cash flow of $23.2M in fiscal year 2025, likely due to heavy capital investments.
